A randomized crossover study of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects

What Was Tested

This randomized controlled trial paper looks at Secretin.

The researchers have developed an endoscopic method of secretin endoscopic pancreatic function testing (ePFT) to simplify duodenal fluid collection.

Validation of the ePFT requires a direct comparison to the traditional PFT using a Dreiling tube (DT).

Their aim was to compare bicarbonate concentrations [HCO3-] obtained by the ePFT and DT methods in healthy subjects (HS).

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

DT protocol: Endoscopic placement of a DT was confirmed by fluoroscopy.

Fluid specimens were auto-analyzed for [HCO3-].

How the Study Was Run

The design is described as randomized and crossover.

Random assignment meant chance, not the researchers, decided who got Secretin and who got the comparison, which limits bias.

Each person switched between Secretin and the comparison at some point, usually with a gap in between.

HS were randomized to either DT or ePFT, then crossed over to the other test after a minimum 1-wk washout.

An age/weight-based sedation bolus was used for each test.

After a baseline 15-min collection and administration of IV synthetic secretin, fluid was continuously collected in 15-min aliquots for an hour. ePFT protocol: Endoscopy was performed using a 6-mm endoscope.

After gastric aspiration and discard and IV secretin, duodenal aspirates were obtained every 15-min for an hour.

What Was Measured

Topics PubMed links to this paper include Bicarbonates, Duodenoscopy, Duodenum, Gastrointestinal Agents, Hydrogen-Ion Concentration, Intestinal Secretions and Intubation, Gastrointestinal.

What This Means in Plain Language

The paper is a randomized and crossover study of Secretin.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (The American journal of gastroenterology), a journal based in United States.

More context: the Secretin compound page, all human trials.